Jon Thor Asmussen

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Multiple Myeloma

Radical Prostatectomy

Bone Mineral Density

Drug Administration

Top Venues

Blood cancer journal

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Schjesvold Fredrik, null null
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal 14 (1) (2024)
Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Schjesvold Fredrik, null null
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal 14 (1) (2024)
Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Schjesvold Fredrik, null null
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal 14 (1) (2024)
Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Schjesvold Fredrik, null null
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal 14 (1) (2024)
Karen Middelbo Buch-Olsen, Mads Hvid Poulsen, Steinbjørn Hansen, Mie Holm Vilstrup, Jorun Holm, Soren Hess, Paw Christian Holdgaard, Karsten Egbert Arnold Zieger, Søren Sørensen Madsen, Oke Gerke, Kasper Tholstrup Pedersen, Johan Hygum Dam, Niels Langkjaer, Louise Dorner Østergaard, Jon Thor Asmussen, Poul-Erik Braad, Birgitte Noergaard, Matthias Eiber, Malene Grubbe Hildebrandt
A randomised trial of [ 18 F]PSMA-1007-PET/CT versus NaF-PET/CT for staging primary prostate cancer: A trial protocol. BJUI compass 4 (5) (2023)
Birgitte Bjørnhart, Karin Holmskov Hansen, Jon Thor Asmussen, Trine Lembrecht Jørgensen, Jørn Herrstedt, Tine Schytte
Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis. Cancers 14 (7) (2022)